Treating Hyperkalemia in Patients with Heart Failure: Making the Right Choices

Hyperkalemia is a barrier to optimization of renin-angiotensin-aldosterone system inhibitor (RAASi) therapy in patients with heart failure (HF).  Novel potassium binders effectively and safely lower serum potassium, potentially enabling HF patients to remain on optimal RAASi therapy.  In this program, experts will 1) emphasize the importance of patients taking RAASi therapy and at target doses, 2) discuss the clinical evidence for using novel potassium binders, and 3) explain the rationale for using novel potassium binders in long-term management.

An accredited satellite program, provided by Voxmedia LLC and supported through an independent educational grant from AstraZeneca